<a href="https://www.fiercebiotech.com/biotech/chutes-ladders-helus-shuffles-out-ceo-after-two-months-adds-experienceto-science-board" hreflang="en">Chutes & Ladders—Helus shuffles out CEO after two months, adds experience to science board</a>
Helus Pharma has replaced CEO Michael Cola after just two months, with co-founder Eric So stepping in as interim CEO while the company strengthens its scientific advisory board. Additionally, Pfizer's chief strategy officer Andrew Baum is leaving, and Paratus Sciences has appointed Alicia Secor as its new CEO to advance its lead drug candidate.
Helus Pharma's recent CEO shuffle highlights the importance of adaptable leadership in advancing next-gen mental health therapies. With industry veterans like Robert Langer and Stephen Brannan joining Helus's scientific advisory board, there's a strategic emphasis on leveraging experienced insights to potentially accelerate drug development. This signals a valuable opportunity to monitor Helus for advancements in mental health treatments, which could become a significant investment focus in the healthtech sector.